Bio-Techne Corporation
NASDAQ:TECHBiotechnology
-$1.03 today
- Market cap
- $11.43B
- Beta
- 1.36
- P/E (TTM)
- 78.3
- EPS (TTM)
- $0.70
- Dividend yield
- 0.58%
Volume 2.63M
Average 2.66M
TECH Financing Cash Flow
Net cash exchanged with lenders and shareholders through borrowing, repayments, buybacks, and dividends.
Bio-Techne CorporationNASDAQ: TECH
Financing Cash Flow · Q1 FY2027 · quarter ended Sep 2026
Financing cash flow turns positive
Q1 FY2027 financing cash flow was $16.39M, compared with -$44.2M a year earlier. Trailing-twelve-month financing cash flow was -$108.53M.
Context
- Financing cash flow amounted to 13.9% of revenue in FY2026, down 6.9 pp from a year earlier.
- Financing cash flow increased in 1 of the last 3 fiscal years.
What to watch
Whether quarterly financing cash flow holds near $16.39M or moves back toward the trailing-twelve-month quarterly average of -$27.13M.
Sources:Cash FlowText generated from reported figures; not investment advice.
Financing Cash Flow history
USD · from the cash flow
- Latest · FY2026
- (169.11M) USD
- Year-over-year change
- +33.4%
| Period | Period end | Financing Cash Flow | YoY change |
|---|---|---|---|
| FY2026 | 2026-06-30 | (169.11M) | +33.4% |
| FY2025 | 2025-06-30 | (253.91M) | -107.4% |
| FY2024 | 2024-06-30 | (122.4M) | -641.2% |
| FY2023 | 2023-06-30 | 22.62M | +109.3% |
| FY2022 | 2022-06-30 | (242.85M) | — |
Financing Cash Flow vs competitors
How TECH compares with its peers on the latest reported figures
- TECH's LTM Sep 2026 financing cash flow of $108.53M is the 6th largest of the 11 companies compared; the peer median is $7.11M.
- Its year-over-year change of -62.1% is the 6th highest of 10, against a peer median of -10.2%.
- Financing cash flow amounts to 8.8% of revenue for TECH, versus a peer median of 9.6%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Sep 2026 | $8.32B | +240.6% | +4.8% | 32.5% | |
| LTM Sep 2026 | $985M | +118.3% | — | 2.1% | |
| LTM Jul 2026 | $503.44M | -67.2% | +8.9% | 17.3% | |
| LTM Jun 2026 | $376.41M | +18.3% | +12.5% | 17.9% | |
| LTM Jun 2026 | $121.1M | -66.0% | — | 4.7% | |
| LTM Sep 2026 | $108.53M | -62.1% | — | 8.8% | |
| LTM Jul 2026 | $95M | -80.6% | -19.5% | 1.3% | |
| LTM Jun 2026 | $35.1M | +205.1% | — | 1.0% | |
| LTM Mar 2026 | $11.67M | -10.2% | — | 77.6% | |
ALMRAlamar Biosciences, Inc. | FY2025 | $10.84M | — | — | 14.6% |
| LTM Jun 2026 | $2.54M | -129.5% | -24.5% | 0.4% | |
| Peer median (excluding TECH) | $7.11M | -10.2% | +4.8% | 9.6% | |
Competitors are the stored peer set for TECH. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2022 Jun 2022 | FY2023 Jun 2023 | FY2024 Jun 2024 | FY2025 Jun 2025 | FY2026 Jun 2026 |
|---|---|---|---|---|---|
| Net Income | 263.1M | 285.44M | 168.07M | 73.4M | 181.86M |
| Depreciation & Amortization | 101.07M | 107.24M | 111.71M | 109.9M | 97.36M |
| Deferred Income Tax | 6.82M | (29.57M) | (39.45M) | (51.11M) | 13.2M |
| Stock-Based Compensation | 42.18M | 39.23M | 38.04M | 40.83M | 41.37M |
| Change in Working Capital | (69.52M) | (90.58M) | (10.11M) | 11.54M | (41.3M) |
| Accounts Receivables | (57.6M) | (23.36M) | (31.13M) | 42.6M | (10.79M) |
| Inventory | (32.01M) | (30.17M) | (14.22M) | (18.14M) | (8.23M) |
| Accounts Payables | 12.74M | (7.91M) | 25.77M | (13.95M) | 3.18M |
| Other Working Capital | 7.35M | (29.14M) | 9.47M | 1.04M | (25.46M) |
| Other Non-Cash Items | (18.38M) | (57.37M) | 30.71M | 102.99M | (406K) |
| Operating Cash Flow | 325.27M | 254.39M | 298.98M | 287.56M | 292.07M |
| Capital Expenditures | (44.91M) | (38.24M) | (62.88M) | (31.01M) | (28.85M) |
| Acquisitions (Net) | 0 | (83.36M) | (169.71M) | (15M) | 4.62M |
| Purchases of Investments | (25M) | (20.5M) | (5.53M) | (5.53M) | 0 |
| Sales of Investments | 26.06M | 108.46M | 28.08M | 1.09M | 6.04M |
| Other Investing Activities | (53M) | (232M) | 7M | 15.26M | 0 |
| Investing Cash Flow | (96.85M) | (265.65M) | (203.03M) | (35.18M) | (18.19M) |
| Debt Repayment | (85.5M) | 94M | (31M) | 27M | (146M) |
| Common Stock Issued | 0 | 0 | 0 | 0 | 80.62M |
| Common Stock Repurchased | (160.95M) | (19.56M) | (80.04M) | (275.73M) | (41.68M) |
| Dividends Paid | (50.19M) | (50.29M) | (50.42M) | (50.39M) | (49.92M) |
| Other Financing Activities | 53.78M | (1.54M) | 39.06M | 45.22M | (12.14M) |
| Financing Cash Flow | (242.85M) | 22.62M | (122.4M) | (253.91M) | (169.11M) |
| Effect of Forex Changes | (12.09M) | (3.36M) | (2.33M) | 11.93M | (2.24M) |
| Net Change in Cash | (26.52M) | 8M | (28.78M) | 10.4M | 102.53M |
| Free Cash Flow | 280.36M | 216.15M | 236.1M | 256.55M | 263.22M |
Bio-Techne Corporation
NASDAQ:TECH
Intrinsic Alpha fair value
Locked
Current Price
$72.75
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.